NASDAQ:MYGN - Myriad Genetics Stock Price, Forecast & News

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its earnings results on Thursday, February, 6th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.01. The firm earned $195.10 million during the quarter, compared to analyst estimates of $209.61 million. The business's revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.38 earnings per share. View Myriad Genetics' Earnings History.

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Myriad Genetics.

Myriad Genetics updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of approx $0.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.02. The company issued revenue guidance of approx $735 million, compared to the consensus revenue estimate of $807.66 million.

8 Wall Street analysts have issued 12-month price objectives for Myriad Genetics' shares. Their forecasts range from $17.00 to $36.00. On average, they expect Myriad Genetics' share price to reach $25.63 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View Analyst Price Targets for Myriad Genetics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.

News articles about MYGN stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myriad Genetics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Myriad Genetics.

Myriad Genetics saw a decrease in short interest in January. As of January 31st, there was short interest totalling 12,820,000 shares, a decrease of 6.2% from the January 15th total of 13,670,000 shares. Based on an average daily volume of 1,025,600 shares, the days-to-cover ratio is presently 12.5 days. Currently, 17.8% of the company's shares are short sold. View Myriad Genetics' Current Options Chain.

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Exelixis (EXEL), Emergent Biosolutions (EBS), Halozyme Therapeutics (HALO), Alkermes (ALKS), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI) and Arena Pharmaceuticals (ARNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alibaba Group (BABA), Kratos Defense & Security Solutions (KTOS), STMicroelectronics (STM) and Gilead Sciences (GILD).

Myriad Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.05%), State Street Corp (5.22%), Earnest Partners LLC (4.84%), Bank of New York Mellon Corp (1.25%), New York State Common Retirement Fund (1.23%) and Rothschild & Co. Asset Management US Inc. (1.19%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

MYGN stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Baillie Gifford & Co., Royce & Associates LP, Point72 Asset Management L.P., Russell Investments Group Ltd., AQR Capital Management LLC, Bank of New York Mellon Corp and Pictet Asset Management Ltd.. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Nicole Lambert, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.

MYGN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Global Alpha Capital Management Ltd., Earnest Partners LLC, FMR LLC, Renaissance Technologies LLC, Great West Life Assurance Co. Can, Credit Suisse AG and Stifel Financial Corp. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYGN stock can currently be purchased for approximately $19.42.